# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

> **NCT02541604** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 87 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT02541604
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-30
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-06-06
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate because limited investigational agent activity was observed.
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02541604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02541604, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02541604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*